TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03611985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiferphane
Description: During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each of the two taxane regimens (weekly paclitaxel or docetaxel every 3 weeks).~All subjects in the phase IIa portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane Chemotherapy
Description: All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
Study: NCT03221803

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OT cap attachment
Description: standard extra coronal attachment
Study: NCT04414709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double short implant
Description: Patients receives 2 short implants to restore missing posterior teeth, loaded with splinted screw retained crowns.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single short implant
Description: Patients receives single short implants, loaded with single screw retained crowns.
Study: NCT06160466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADe colonoscopy using GI Genius device
Description: We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a follow-up pateints in the screening population.
Study: NCT04361695

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hemorrhoidectomy
Description: The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprophenum
Description: Ketoprophenum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06160466

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: White light
Description: White light endoscopy
Study: NCT03349216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Regional Anesthesia
Description: in this research patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes (A.T.S. 2000, Zimmer, Inc., Bloomfield, CN) will be deflated (hence named Rapid MiniBier's block). the pain score will be assessed by NRS system before during and after the procedure.
Study: NCT04215159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab biosimilar
Description: 1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: 1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: 100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks.
Study: NCT02005458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Study: NCT01312558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prudent diet group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet group
Study: NCT03426189

Intervention type: PROCEDURE
Intervention: Leukapheresis
Description: Blood will be taken by a needle inserted into a vein in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out of the machine for purposes of this research. The rest of the blood will be returned through a needle in the other arm.

Intervention type: PROCEDURE
Intervention: Lymph node biopsy
Description: Ultrasound will be used to localize the position of one lymph node in the groin. Under a light general anesthetic, one lymph node will be removed.
Study: NCT03524521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Training
Description: Interval training is prescribed 3 days per week using 5 body weight exercises in a progressive fashion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Walking prescribed to meet current exercise guidelines; 150 minutes per week.
Study: NCT01525914

Intervention type: DRUG
Intervention: Dutasteride
Description: dutasteride 0.5mg daily
Study: NCT05392218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: consisted of six sessions (twice each week) up to 30 minutes of individual sessions. Each session contained a different component and topic that included substance abuse, physical activity, healthy sleep, stress management, nutrition and social support. The components in order were randomized for each participant.
Study: NCT00479973

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamonforce
Description: Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. 2 capsules after the two largest meals of the day
Study: NCT01522963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
Study: NCT05392218

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: general health education
Description: rceived the same amount of virtual session equivalent to MI form. However, the structure of the sessions consisted of brief advice to promote healthy lifestyle delivered by different therapists
Study: NCT02841982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-injection QLB(quadratus lumborum block)
Description: Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philip CX50 Ultrasound Scanner
Description: The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
Study: NCT02307331

Intervention type: DEVICE
Group type: OTHER
Intervention: Optivac
Description: A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results

Intervention type: DEVICE
Group type: OTHER
Intervention: Optivac
Description: A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results

Intervention type: DEVICE
Group type: OTHER
Intervention: Optipac
Description: A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system

Intervention type: DEVICE
Group type: OTHER
Intervention: Optipac
Description: A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system

Intervention type: DEVICE
Group type: OTHER
Intervention: Arcom (Exceed cup)
Description: The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene

Intervention type: DEVICE
Group type: OTHER
Intervention: Arcom (Exceed cup)
Description: The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene

Intervention type: DEVICE
Group type: OTHER
Intervention: E1 (Exceed cup)
Description: The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.

Intervention type: DEVICE
Group type: OTHER
Intervention: E1 (Exceed cup)
Description: The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sirius stem
Description: A polished tapered stem

Intervention type: DEVICE
Group type: OTHER
Intervention: Sirius stem
Description: A polished tapered stem

Intervention type: DEVICE
Group type: OTHER
Intervention: Sirius stem
Description: A polished tapered stem
Study: NCT00106496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic
Description: topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic
Description: topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic
Description: topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic
Description: topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: topical
Study: NCT01444989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AKRQ questionnaire
Description: The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
Study: NCT02841982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAJUNK StimuLong
Study: NCT01444989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AKRQ questionnaire
Description: The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skindex-16, DLQI, Skin Health Calculator
Description: These are all previously validated questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skindex-16, DLQI, Skin Health Calculator
Description: These are all previously validated questionnaires
Study: NCT02841982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose ropivacaine
Description: * 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~* given immediately after the correct position of the tip of the needle has been verified.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine given as IPCA(intravenous patient controlled analgesia)
Description: bolus: 1.5\~2mg, lock time: 10min, 1h limitation: 6\~8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine given as IPCA(intravenous patient controlled analgesia)
Description: bolus: 1.5\~2mg, lock time: 10min, 1h limitation: 6\~8mg
Study: NCT03151174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 10000 UNT
Description: 10000 IU Vitamin D per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 5000 UNT
Description: 5000 IU Vitamin D per day
Study: NCT04469777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Study: NCT03349216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Analgesia
Description: in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
Study: NCT00127712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Study: NCT02267460

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AA4500
Study: NCT02281422

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093
Study: NCT02281422

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093
Study: NCT02267460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ErecAid® Esteem® Manual Vacuum Therapy System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ErecAid® Esteem® Manual Vacuum Therapy System
Study: NCT04222582

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
Study: NCT03465878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered via SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered via SC injection
Study: NCT02267460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Investigator Modeling
Study: NCT02201784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Comparison of Equipotent doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Comparison of equipotent doses
Study: NCT03685214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Description: we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
Study: NCT03465878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered via SC injection
Study: NCT03685214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactated Ringer's solution
Description: we use balanced balanced crystalloids in ICU patients with sepsis for resuscitation fluid.
Study: NCT01868347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment
Description: preemptive PEEP before pneumoperitoneum and trendelenburg
Study: NCT04122235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LETSGO follow-up
Description: Nurse-led follow-up in 50% of the consultations Access to the LETSGO-app
Study: NCT04014452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
Study: NCT00542581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Acrysof toric SN60T3 IOL
Description: Intraocular Lens
Study: NCT01868347

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: PEEP after pneumoperitoneum and trendelenburg
Study: NCT04174625

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Omega3-FA
Description: Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Omega3-FA
Description: Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
Study: NCT03188991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
Study: NCT01184274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB939
Description: Dose Levels for Part A~-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~1. (starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~2. - 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~3. - 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing
Study: NCT03188991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
Study: NCT01728194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 20 mg target dose for 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Structural and functional MRI of the brain for research purposes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Structural and functional MRI of the brain for research purposes.
Study: NCT04864197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Description: prf membrane placement over implant site for gingival thickening

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Description: prf membrane placement over implant site for gingival thickening
Study: NCT02581501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAX - Gemcitabine, Abraxane and Xeloda
Description: GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
Study: NCT01097057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Given through catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT02683031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ca2+ ionophore
Description: Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
Study: NCT00207363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin, Peg interferon alfa 2b
Description: Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction therapy
Description: Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
Study: NCT03682926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-stimulation
Description: Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electro-stimulation
Description: Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.